Status:
COMPLETED
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
Lead Sponsor:
University of Michigan Rogel Cancer Center
Collaborating Sponsors:
Department of Health and Human Services
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hematologic Diseases
Eligibility:
All Genders
5-75 years
Phase:
NA
Brief Summary
The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous...
Detailed Description
Health information technology tools may enable caregivers and patients to become more active participants in their healthcare.This study is not to provide any treatment, but rather to investigate the ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- The caregiver must have an eligible patient (see below)
- The caregiver must be of age ≥18 years.
- The caregiver should be comfortable in reading and speaking English and signing informed consents.
- The caregiver should provide at least 50% of care needs.
- An eligible patient is one who identifies the eligible caregiver as their primary caregiver (i.e., provides at least 50% of care needs).
- An eligible patient is age ≥5 years.
- An eligible patient is scheduled to undergo HCT.
- An eligible patient is able to sign informed consent/assent forms.
- Patients and caregivers agree to provide informed consent that is in regulatory compliance and IRBMED-approved and also in accordance to institutional guidelines. A patient is able to undergo HCT at the U-M only if a designated family caregiver (e.g., parents, adult children, spouses, family members, neighbors, friends) accepts the roles, in accordance to the Clinical Practice Guidelines of the U-M BMT Program.
- The caregiver and patient must have his/her own smartphone to participate.
- Exclusion Criteria
- \- Patient does not meet eligibility criteria to undergo HCT at the U-M BMT Program or Oregon Health \& Sciences University.
Exclusion
Key Trial Info
Start Date :
September 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 11 2024
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT04094844
Start Date
September 8 2020
End Date
August 11 2024
Last Update
January 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States, 48109
2
Oregon Health & Science University
Portland, Oregon, United States, 97239